+208.1%
LRCX vs MRNA
+511.3%
-303.2%
-41.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.1% | -2.2% | +7.4% | +5.1% |
| 7D | +1.9% | +5.5% | -3.6% | +1.9% |
| 30D | +0.1% | +158.7% | -158.7% | -1.8% |
| 3M | -8.5% | +182.1% | -190.6% | -14.2% |
| 6M | +38.1% | +151.8% | -113.8% | +31.6% |
| YTD | +80.1% | +393.6% | -313.5% | +46.7% |
| 1Y | +208.1% | +499.5% | -291.4% | +136.5% |
| All | +208.1% | +511.3% | -303.2% | +136.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling